Loading...
Model‐Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non–Small Cell Lung Cancer
Nivolumab is the first anti–programmed death‐1 agent approved in China for treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC). Here, we characterize the population pharmacokinetics (PPK) of nivolumab monotherapy in Chinese patients with previously treated advanced/recurre...
Na minha lista:
| Udgivet i: | J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6767401/ https://ncbi.nlm.nih.gov/pubmed/31115908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1432 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|